



OFFICE OF THE CHANCELLOR

9500 GILMAN DRIVE # 0005  
LA JOLLA, CALIFORNIA 92093-0005  
TELEPHONE: (858) 534-3135  
FAX: (858) 534-6523

December 17, 2014

To: President Janet Napolitano  
The Regents of the University of California  
Dr. Maike Sander, Professor of Pediatrics, UC San Diego

Subject: Chancellor's Determination and Rationale for Submission of a Proposal to Japan Tobacco, Inc.

In compliance with [Regent Policy 2309](#), I have reviewed all relevant information and submit my written approval regarding the submission of a sponsored research proposal to Japan Tobacco, Inc. Following is a summary of the background and my rationale.

Dr. Maike Sander, Principal Investigator in Pediatrics, was approached by Akros Pharma, Inc., a U.S. subsidiary of Japan Tobacco Inc., to submit a proposal for research involving pediatric diabetes. The aim of the potential research is to identify novel regulators of pancreatic beta cell proliferation, using both mouse and human cells. The proposed research agreement is for a total of \$563,046 (including full indirect costs).

In accordance with the policy, a peer review committee was convened and comprised of distinguished faculty Dr. Paul Insel (Pharmacology), Dr. Robert Ross (Cardiology) and Dr. Susan Taylor (Chemistry and Biochemistry). They completed a review of the scope of work and outlined their recommendation, which is summarized as follows (attachment 1):

- a. There is no clear aspect of this scientific plan that would positively or negatively influence marketing or other aspects of the tobacco industry.
- b. None of the proposed studies involve the use of tobacco products.
- c. Overall, the proposed studies have the potential to yield new agents that could enhance beta cell proliferation.
- d. None of the material from the applicant or found in the Research Collaboration document from Akros Pharma, Inc., suggests that the industry sponsor will influence the outcome of the scientific pursuit in any way.
- e. Given this, the review committee recommends that the faculty member be permitted to apply for funds from this tobacco-related industry source.

In consultation with Vice Chancellor for Research Sandra A. Brown, I hereby confirm that my rationale for approving this request is based on the committee's compelling conclusions. A copy of the complete review report is attached.


By way of background, since Regent Policy 2309 was enacted, there has been no other case where a UC campus has been presented with an opportunity to apply for funding from a tobacco company. Stanford

University, however, has conducted research with this company. In addition, a faculty member at the Gladstone Institute (an independent non-profit affiliated with UC San Francisco) has received funding for drug development in HIV from Japan Tobacco.

Should this research project be selected for funding, there are a number of issues in the proposed terms of the agreement related to potential joint ownership of IP, licensing rights and royalties, visiting scientists from Japan Tobacco, Inc., press releases about any resulting collaborative relationship, and publication in scientific journals, to name a few. With my approval of this opportunity, I have directed the campus Contract & Grant Office to negotiate these terms to limit the University's public exposure and be in conformance with the University's contracting policies and standard practices.

This letter confirms my approval of this request and satisfies the Regents Policy 2309 requirement for a written determination. This signed approval will be distributed accordingly.

Sincerely,



Pradeep Khosla,  
Chancellor

Attachment: Review Committee Report

Route approval to:

Dr. Maïke Sander

President Napolitano (via Vice President Tucker)

The Regents of the University of California (via Vice President Tucker)

c: Vice Chancellor Sandra A. Brown

October 22, 2014

**RE-89 Evaluation of Proposed Tobacco Related Research Funding - Professor Maike Sander, Pediatrics with Akros/Japan Tobacco Pharma**

Prepared by Robert Ross, Professor IR, Cardiology  
UC San Diego

**Review Committee**

Paul Insel, Professor of Pharmacology  
Robert Ross, Professor IR, Cardiology  
Susan Taylor, Professor, Chemistry and Biochemistry

The RE-89 review committee has reviewed Dr. Maike Sander's proposed application to Akros/Japan Pharma as required by the University of California Regents Resolution RE-89, which states that research proposals to be funded by the Tobacco Industry must undergo scientific review by faculty members. The proposal put forth by Dr. Sander is planned for submission to Akros Pharma Inc., a U.S. subsidiary of Japan Tobacco Pharma, the pharmaceutical component of Japan Tobacco.

The aim of the proposal is to identify novel regulators of pancreatic beta cell proliferation, using both mouse and human cells. There is no clear aspect of this scientific plan that would positively or negatively influence marketing or other aspects of the tobacco industry.

Based on the supplied material, the proposal uses sound methodology the work plan will enable the researcher to test valid scientific hypotheses to reach objective and scientifically valid conclusions. Data from the initial proteomic studies have identified a number of proteins whose activity and expression may relate to age-related changes in pancreatic beta cell proliferation. None of the proposed studies involve the use of tobacco products. Overall, the proposed studies have the potential to yield new agents that could enhance beta cell proliferation.

None of the material from the applicant or found in the Research Collaboration document from Akros, suggest that the industry sponsor will influence the outcome of the scientific pursuit in any way. Given this, the review committee recommends that the faculty member be permitted to apply for funds from this tobacco-related industry source.